Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NTRK1 | P04629 | 17/20 | 0.64 |
| ▸ | JAK2 | O60674 | 2/20 | 0.62 |
| ▸ | JAK3 | P52333 | 2/20 | 0.62 |
| ▸ | IGF1R | P08069 | 3/20 | 0.47 |
| ▸ | NTRK3 | Q16288 | 1/20 | 0.46 |
| ▸ | NTRK2 | Q16620 | 1/20 | 0.46 |
| ▸ | LIMK1 | P53667 | 1/20 | 0.45 |
| ▸ | LIMK2 | P53671 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2568330 | 1.00 | NTRK1 (0.64) | NTRK1JAK2JAK3IGF1RNTRK3 | |
| SCHEMBL5029635 | 0.90 | NTRK1 (0.68) | NTRK1JAK2JAK3LIMK1LIMK2 | |
| SCHEMBL5029637 | 0.90 | NTRK1 (0.68) | NTRK1JAK2JAK3LIMK1LIMK2 | |
| SCHEMBL2568571 | 0.88 | NTRK1 (0.69) | NTRK1JAK2JAK3IGF1RLIMK1 | |
| SCHEMBL2568572 | 0.88 | NTRK1 (0.69) | NTRK1JAK2JAK3IGF1RLIMK1 | |
| SCHEMBL5029612 | 0.88 | NTRK1 (0.66) | NTRK1JAK2JAK3LIMK1LIMK2 | |
| SCHEMBL5029614 | 0.88 | NTRK1 (0.66) | NTRK1JAK2JAK3LIMK1LIMK2 | |
| SCHEMBL5032152 | 0.85 | JAK2 (0.74) | NTRK1JAK2JAK3LIMK1LIMK2 | |
| SCHEMBL2571424 | 0.85 | NTRK1 (0.73) | NTRK1JAK2JAK3IGF1RNTRK3 | |
| SCHEMBL2571422 | 0.85 | NTRK1 (0.73) | NTRK1JAK2JAK3IGF1RNTRK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2383268-B1 | PYRAZOLYLAMINOPYRIDINE DERIVATIVES USEFUL AS KINASE INHIBITORS | ASTRAZENECA AB (SE) | 2015-09-02 | — | — | EP | disclosed |
| EP-2383268-A1 | Pyrazolylaminopyridine derivatives useful as kinase inhibitors | AstraZeneca AB (SE) | 2011-11-02 | — | — | EP | disclosed |
| EP-2164490-A1 | PYRAZOLYL DERIVATIVES WITH ANALGESIC ACTIVITY AND THEREFORE USEFUL IN THE TREATMENT OR PROPHYLAXIS OF PAIN. | AstraZeneca AB (SE) | 2010-03-24 | — | — | EP | disclosed |
| WO-2008054292-A1 | PYRAZOLYL DERIVATIVES WITH ANALGESIC ACTIVITY AND THEREFORE USEFUL IN THE TREATMENT OR PROPHYLAXIS OF PAIN. | ASTRAZENECA AB (SE) | 2008-05-08 | — | — | WO | disclosed |
| US-20080108669-A1 | Use 541 | ASTRAZENECA AB (SE) | 2008-05-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080108669-A1 | Use 541 | TRPV1, P2RX3, P2RX5 | NTRK1 3837/4885JAK2 1797/4885JAK3 2868/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.